NCT00620867COMPLETEDanonymous

A Study of the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) and Three Times Daily Ibuprofen vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee

Sponsor

Source record

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase

Source record

PHASE4

Modality

AI-normalized

small molecule

Target

AI-normalized

Ibuprofen, celecoxib, placebo

Indication / condition

AI-normalized

Osteoarthritis, Knee

Intervention

Source record

Ibuprofen, celecoxib, placebo

Related intelligence directories

Indication directory: Osteoarthritis Modality directory: small molecule Target directory: Ibuprofen

Source & freshness

Source record

NCT ID

NCT00620867

Original source

ClinicalTrials.gov

Source last updated

Feb 21, 2021

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT00620867

Title

A Study of the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) and Three Times Daily Ibuprofen vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Status

COMPLETED

Phase

PHASE4

Condition raw

Osteoarthritis, Knee

Condition normalized

Osteoarthritis, Knee

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Ibuprofen, celecoxib, placebo

Target normalized

Ibuprofen, celecoxib, placebo

Interventions

Ibuprofen, celecoxib, placebo

Public preview

Source record

To compare the efficacy and safety of celecoxib versus ibuprofen in subjects with osteoarthritis (OA) of the knee.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Study of the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) and Three Times Daily Ibuprofen vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 20, 2026

NCT ID

NCT00620867

Status

COMPLETED

Phase

PHASE4

Sponsor

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Executive brief

Investment-Ready Snapshot

To compare the efficacy and safety of celecoxib versus ibuprofen in subjects with osteoarthritis (OA) of the knee.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedFeb 21, 2021

Internal syncJun 09, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT00620867

Indication

Osteoarthritis, Knee

Modality

small molecule

Target

Ibuprofen, celecoxib, placebo

Intervention

Ibuprofen, celecoxib, placebo

Source record